CA2446064A1 - Nitrosated and nitrosylated nebivolol and its metabolites, compositions and methods of use - Google Patents

Nitrosated and nitrosylated nebivolol and its metabolites, compositions and methods of use Download PDF

Info

Publication number
CA2446064A1
CA2446064A1 CA002446064A CA2446064A CA2446064A1 CA 2446064 A1 CA2446064 A1 CA 2446064A1 CA 002446064 A CA002446064 A CA 002446064A CA 2446064 A CA2446064 A CA 2446064A CA 2446064 A1 CA2446064 A1 CA 2446064A1
Authority
CA
Canada
Prior art keywords
nitric oxide
hypertension
compound
disease
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002446064A
Other languages
English (en)
French (fr)
Inventor
David S. Garvey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nicox SA
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2446064A1 publication Critical patent/CA2446064A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Prostheses (AREA)
  • Pyrane Compounds (AREA)
CA002446064A 2001-05-02 2002-05-01 Nitrosated and nitrosylated nebivolol and its metabolites, compositions and methods of use Abandoned CA2446064A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28772501P 2001-05-02 2001-05-02
US60/287,725 2001-05-02
PCT/US2002/013667 WO2002087508A2 (en) 2001-05-02 2002-05-01 Nitrosated and nitrosylated nebivolol and its metabolites, compositions and methods of use

Publications (1)

Publication Number Publication Date
CA2446064A1 true CA2446064A1 (en) 2002-11-07

Family

ID=23104065

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002446064A Abandoned CA2446064A1 (en) 2001-05-02 2002-05-01 Nitrosated and nitrosylated nebivolol and its metabolites, compositions and methods of use

Country Status (8)

Country Link
US (2) US7138430B2 (https=)
EP (1) EP1406608B1 (https=)
JP (2) JP2004528337A (https=)
AT (1) ATE437637T1 (https=)
AU (1) AU2002338528B2 (https=)
CA (1) CA2446064A1 (https=)
DE (1) DE60233140D1 (https=)
WO (1) WO2002087508A2 (https=)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10053397A1 (de) 2000-10-20 2002-05-02 Schering Ag Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
JP2007502831A (ja) * 2003-08-20 2007-02-15 ニトロメッド インコーポレーティッド ニトロソ化およびニトロシル化心血管化合物、組成物、ならびに使用方法
CN1930304B (zh) * 2003-11-21 2016-01-06 Anp技术公司 不对称支化的聚合物缀合物和微阵列检测
CA2554716A1 (en) * 2004-01-22 2005-08-04 Nitromed, Inc. Nitrosated and/or nitrosylated compounds, compositions and methods of use
ES2543836T3 (es) * 2004-04-23 2015-08-24 Northern Sydney Local Health District Procedimientos y composiciones para el tratamiento de afecciones miocárdicas
US7838552B2 (en) * 2004-06-04 2010-11-23 Forest Laboratories Holdings Limited Compositions comprising nebivolol
US7803838B2 (en) * 2004-06-04 2010-09-28 Forest Laboratories Holdings Limited Compositions comprising nebivolol
ES2282062T1 (es) 2004-06-04 2007-10-16 Teva Pharmaceutical Industries Ltd. Composicion farmaceutica que contiene irbesartan.
CN101862322A (zh) 2004-07-30 2010-10-20 托伦特药物有限公司 奈必洛尔及其药学可接受盐、制备方法以及奈必洛尔的药物组合物
EP1781331A1 (en) * 2004-08-09 2007-05-09 Université Catholique de Louvain Use of agonists and antagonists of beta-adrenoceptors for treating arterial diseases
WO2006083779A2 (en) * 2005-01-31 2006-08-10 Mylan Laboratories, Inc. Pharmaceutical composition comprising hydroxylated nebivolol
RU2413518C2 (ru) * 2005-01-31 2011-03-10 Милан Лэборетериз, Инк. Глюкуронидированные метаболиты небиволола
US20060222592A1 (en) * 2005-04-05 2006-10-05 Clemens Burda Nanoparticles and methods of manufacturing nanoparticles for electronic and non-electronic applications
EP1877553B1 (en) 2005-05-02 2011-01-19 ANP Technologies, Inc. Polymer conjugate enhanced bioassays
AP2896A (en) * 2005-05-31 2014-05-31 Mylan Lab Inc Compositions comprising nebivolol
RU2441653C2 (ru) * 2005-05-31 2012-02-10 Милан Лэборетериз, Инк. Композиции, содержащие небиволол
EP1943361A4 (en) * 2005-10-04 2009-04-15 Nitromed Inc GENETIC RISK ASSESSMENT IN CARDIAC SUFFICIENCY: IMPACT OF GENETIC VARIATION OF ALDOSTERONE SYNTHASE PROMOTIVE POLYMORPHISM
US20070154466A1 (en) * 2005-12-30 2007-07-05 Jan Weber Internal medical devices containing peroxide-converting catalysts
US20080193385A1 (en) * 2007-02-08 2008-08-14 Todd Maibach Compositions and methods for treating neuropathy
CA2599082A1 (en) * 2007-08-27 2009-02-27 Ping I. Lee Supramacromolecular polymer complexes providing controlled nitric oxide release for healing wounds
US20110014174A1 (en) * 2007-08-28 2011-01-20 University Of Manitoba Lysozyme, A Novel Vasodilator of Sepsis that can be inhibited by a Peroxidase and Hydroxyl Radical Scavengers
KR20100065190A (ko) 2007-09-14 2010-06-15 닛토덴코 가부시키가이샤 약물 담체
CA2732513C (en) 2008-08-01 2017-04-25 Arca Biopharma, Inc. Methods and compositions involving (s)-bucindolol
HUP0800498A2 (en) * 2008-08-06 2010-03-29 Semmelweis Egyetem Use of dihydralazine for the preparation of medicaments for treatment of diseases related to ssao level
US8579964B2 (en) 2010-05-05 2013-11-12 Neovasc Inc. Transcatheter mitral valve prosthesis
US11207109B2 (en) 2010-10-20 2021-12-28 206 Ortho, Inc. Method and apparatus for treating bone fractures, and/or for fortifying and/or augmenting bone, including the provision and use of composite implants, and novel composite structures which may be used for medical and non-medical applications
US9554897B2 (en) 2011-04-28 2017-01-31 Neovasc Tiara Inc. Methods and apparatus for engaging a valve prosthesis with tissue
US9308087B2 (en) 2011-04-28 2016-04-12 Neovasc Tiara Inc. Sequentially deployed transcatheter mitral valve prosthesis
CN102977068A (zh) * 2012-05-03 2013-03-20 中国药科大学 一氧化氮供体型异色满酮类衍生物、其制备方法及用途
US9345573B2 (en) 2012-05-30 2016-05-24 Neovasc Tiara Inc. Methods and apparatus for loading a prosthesis onto a delivery system
US20150362475A1 (en) * 2013-01-18 2015-12-17 Synlab Services Gmbh Prediction of kidney disease progression using homoarginine as a biomarker
US9572665B2 (en) 2013-04-04 2017-02-21 Neovasc Tiara Inc. Methods and apparatus for delivering a prosthetic valve to a beating heart
US10631984B2 (en) 2015-12-15 2020-04-28 Neovasc Tiara Inc. Transseptal delivery system
EP4183372A1 (en) 2016-01-29 2023-05-24 Neovasc Tiara Inc. Prosthetic valve for avoiding obstruction of outflow
US11173235B2 (en) 2016-07-15 2021-11-16 Cook Regentec Llc Nitrite eluting devices and methods of use thereof
US11096781B2 (en) 2016-08-01 2021-08-24 Edwards Lifesciences Corporation Prosthetic heart valve
AU2017362500B2 (en) 2016-11-17 2024-09-26 Renovion, Inc. Treatment of Respiratory Tract Diseases and Infections with Ascorbic Acid Compositions
EP3541462A4 (en) 2016-11-21 2020-06-17 Neovasc Tiara Inc. METHODS AND SYSTEMS FOR THE QUICK RETURN OF A TRANSCATHETER HEART VALVE RELEASE SYSTEM
CN111263622A (zh) 2017-08-25 2020-06-09 内奥瓦斯克迪亚拉公司 顺序展开的经导管二尖瓣假体
BR112020009910A2 (pt) 2017-11-17 2020-11-03 Renovion, Inc. composições de ácido ascórbico estáveis e métodos de usar as mesmas
ES3040411T3 (en) 2018-03-22 2025-10-30 Incarda Therapeutics Inc A novel method to slow ventricular rate
CN116585308B (zh) 2018-05-25 2025-10-28 Arca生物制药有限公司 涉及布新洛尔治疗心房颤动的方法和组合物
EP3876870B1 (en) 2018-11-08 2023-12-20 Neovasc Tiara Inc. Ventricular deployment of a transcatheter mitral valve prosthesis
AU2020233892A1 (en) 2019-03-08 2021-11-04 Neovasc Tiara Inc. Retrievable prosthesis delivery system
US11602429B2 (en) 2019-04-01 2023-03-14 Neovasc Tiara Inc. Controllably deployable prosthetic valve
WO2020210652A1 (en) 2019-04-10 2020-10-15 Neovasc Tiara Inc. Prosthetic valve with natural blood flow
US11779742B2 (en) 2019-05-20 2023-10-10 Neovasc Tiara Inc. Introducer with hemostasis mechanism
US11311376B2 (en) 2019-06-20 2022-04-26 Neovase Tiara Inc. Low profile prosthetic mitral valve
ES2987079T3 (es) 2020-08-24 2024-11-13 Edwards Lifesciences Corp Sistemas para alinear una comisura de una válvula cardiaca protésica con una comisura de una válvula nativa
WO2022198259A1 (en) * 2021-03-25 2022-09-29 The Heart Research Institute Ltd Treatment methods for pulmonary arterial hypertension
KR20240131358A (ko) 2022-01-04 2024-08-30 레노비온, 아이엔씨. 글루타치온 염을 포함하는 수용액

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US311175A (en) 1885-01-27 And joseph l
CA1337429C (en) 1983-12-05 1995-10-24 Guy Rosalia Eugene Van Lommen Derivatives of 2,2'-iminobisethanol
US4654362A (en) * 1983-12-05 1987-03-31 Janssen Pharmaceutica, N.V. Derivatives of 2,2'-iminobisethanol
US4868179A (en) 1987-04-22 1989-09-19 Cohn Jay N Method of reducing mortality associated with congestive heart failure using hydralazine and isosorbide dinitrate
CA1337432C (en) 1988-03-23 1995-10-24 Raymond M. Xhonneux Method of lowering the blood pressure
US5428061A (en) 1988-09-15 1995-06-27 Schwarz Pharma Ag Organic nitrates and method for their preparation
US5284872A (en) 1989-09-12 1994-02-08 Schwarz Pharma Ag Nitrato alkanoic acid derivatives, methods for their production, pharmaceutical compositions containing the derivatives and medicinal uses thereof
US5380758A (en) 1991-03-29 1995-01-10 Brigham And Women's Hospital S-nitrosothiols as smooth muscle relaxants and therapeutic uses thereof
AU3071592A (en) 1991-11-14 1993-06-15 Brigham And Women's Hospital Nitrosylation of protein sh groups and amino acid residues as a therapeutic modality
US5910316A (en) 1992-08-24 1999-06-08 The United States Of America, As Represented By The Department Of Health And Human Services Use of nitric oxide-releasing agents to treat impotency
US5650447A (en) 1992-08-24 1997-07-22 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Nitric oxide-releasing polymers to treat restenosis and related disorders
DE4321306A1 (de) 1993-06-26 1995-01-05 Sanol Arznei Schwarz Gmbh Disulfide
TW355683B (en) 1994-02-17 1999-04-11 Janssen Pharmaceutica Nv Composition containing micronized nebivolol
SK282144B6 (sk) * 1994-12-28 2001-11-06 Janssen Pharmaceutica N. V. Liečivo na terapeutické a profylaktické ošetrenie degeneratívnych chorôb vaskulárneho systému a nervovej sústavy, ktoré súvisia s oxidačným stresom
US5703073A (en) 1995-04-19 1997-12-30 Nitromed, Inc. Compositions and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs
US5932538A (en) 1996-02-02 1999-08-03 Nitromed, Inc. Nitrosated and nitrosylated α-adrenergic receptor antagonist compounds, compositions and their uses
US5807847A (en) 1996-06-04 1998-09-15 Queen's University At Kingston Nitrate esters
US6310052B1 (en) 1996-06-04 2001-10-30 Queen's University At Kingston Nitrate esters and their use for neurological conditions
WO1998019672A1 (en) 1996-11-01 1998-05-14 Nitromed Inc. Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
IT1295694B1 (it) 1996-11-14 1999-05-27 Nicox Sa Nitrossi derivati per la preparazione di medicamenti ad attivita antitrombinica
IT1292426B1 (it) 1997-06-27 1999-02-08 Nicox Sa Sali nitrati di ace-inibitori
JP4856295B2 (ja) 1997-07-03 2012-01-18 アメリカ合衆国政府 新規な一酸化窒素放出アミジン誘導ジアゼニウムジオレート及びその組成物
IT1301759B1 (it) 1998-06-19 2000-07-07 Nicox Sa Sali nitrati di farmaci antiipertensivi
WO2000049993A2 (en) 1999-02-24 2000-08-31 Nitromed, Inc. Nitrosated and nitrosylated steroids for the treatment of cardiovascular diseases and disorders
AU3713600A (en) 1999-03-01 2000-09-21 Nitromed, Inc. Nitrosated and nitrosylated prostaglandins, compositions and metods of use
IT1308633B1 (it) 1999-03-02 2002-01-09 Nicox Sa Nitrossiderivati.
IT1311923B1 (it) 1999-04-13 2002-03-20 Nicox Sa Composti farmaceutici.
IT1311921B1 (it) 1999-04-13 2002-03-20 Nicox Sa Composti farmaceutici.
IT1311924B1 (it) 1999-04-13 2002-03-20 Nicox Sa Composti farmaceutici.
US6417207B1 (en) 1999-05-12 2002-07-09 Nitromed, Inc. Nitrosated and nitrosylated potassium channel activators, compositions and methods of use
IT1314184B1 (it) * 1999-08-12 2002-12-06 Nicox Sa Composizioni farmaceutiche per la terapia di condizioni di stressossidativo
US6635273B1 (en) * 1999-10-29 2003-10-21 Trustees Of Boston University Methods of treating vascular diseases characterized by nitric oxide insufficiency
IT1320176B1 (it) 2000-12-22 2003-11-26 Nicox Sa Dispersioni solide di principi attivi nitrati.
RU2006119528A (ru) 2003-12-02 2008-01-10 Никокс С.А. (Fr) Нитрооксипроизводные карведилола и других бета-блокаторов в качестве антигипертензивных средств
BRPI0417182A (pt) 2003-12-02 2007-03-06 Nicox Sa composto e/ou os enantiÈmeros, diastereoisÈmeros e sais farmaceuticamente aceitáveis do mesmo, uso do mesmo, e, composição farmacêutica

Also Published As

Publication number Publication date
EP1406608A2 (en) 2004-04-14
EP1406608B1 (en) 2009-07-29
JP2010248226A (ja) 2010-11-04
WO2002087508A2 (en) 2002-11-07
ATE437637T1 (de) 2009-08-15
US7138430B2 (en) 2006-11-21
US7384976B2 (en) 2008-06-10
AU2002338528B2 (en) 2008-01-24
US20060009513A1 (en) 2006-01-12
WO2002087508A3 (en) 2003-12-11
US20040132805A1 (en) 2004-07-08
DE60233140D1 (de) 2009-09-10
JP2004528337A (ja) 2004-09-16
EP1406608A4 (en) 2004-10-20

Similar Documents

Publication Publication Date Title
US7384976B2 (en) Nebivolol and its metabolites in combination with nitric oxide donors, compositions and methods of use
AU2002338528A1 (en) Nitrosated and nitrosylated nebivolol and its metabolites, compositions and methods of use
JP2004528337A5 (https=)
US7537785B2 (en) Composition for treating vascular diseases characterized by nitric oxide insufficiency
US6656966B2 (en) Nitrosated and nitrosylated taxanes, compositions and methods of use
US20040005306A1 (en) Methods of treating vascular diseases characterized by nitric oxide insufficiency
AU2001259399B2 (en) Methods of treating vascular diseases characterized by nitric oxide insufficiency
US7345053B2 (en) Nitrosated and nitrosylated rapamycin compounds, compositions and methods of use
AU780261B2 (en) Methods of treating vascular diseases characterized by nitric oxide insufficiency
AU2001259399A1 (en) Methods of treating vascular diseases characterized by nitric oxide insufficiency
US20060009431A1 (en) Nitrosated and nitrosylated compounds, compositions and methods use
AU2003223491A1 (en) Nitric oxide donors, compositions and methods of use
US20040105850A1 (en) Methods of treating vascular diseases characterized by nitric oxide insufficiency
AU2008201838B2 (en) Nitrosated and nitrosylated nebivolol and its metabolites, compositions and methods of use

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued